Altered Faecal Microbiome and Metabolome in CT1D, AT1D and T2D

Second Xiangya Hospital of Central South University372 enrolled

Overview

To elucidate the characteristics of global gut microbiota and fecal/serum metabolites in patients with childhood-onset type 1 diabetes, adult-onset type 1 diabetes or type 2 diabetes.

Type 1 diabetes is caused by autoimmune destruction of pancreatic beta cells, leading to severe insulin deficiency and requiring insulin therapy. It is typically considered a disease of childhood and adolescence, but recent epidemiological data have shown that over half of all new-onset type 1 diabetes cases occur in adults worldwide. There are genetic, immune and metabolic differences between adult- and childhood-onset type 1 diabetes, revealing the underlying molecular basis of type 1 diabetes onset at diverse ages may differ. Accurate diagnosis is of great importance because the best treatment for different types of diabetes is divergent. Misdiagnosing type 2 diabetes as type 1 diabetes can lead to unnecessary initial insulin therapy, resulting in higher costs and more side effects. Thus, it is critical to identify the molecular basis and new diagnostic biomarkers for adult-onset type 1 diabetes. Nonetheless, environmental exposures, in particular the immense intestinal microbiota and its derivatives, have been widely investigated. Indeed, patients with childhood-onset type 1 diabetes or type 2 diabetes exhibit compositional alterations in gut microbiota. However, gut microbiota in adult-onset type 1 diabetes has not been elucidated, and little is known about the shared and distinct microbial characteristics in adult-onset type 1 diabetes versus childhood-onset type 1 diabetes or type 2 diabetes. Thus, this study is a cross-sectional study. 4 groups of subjects were recruited for metagenome and metabolome analysis, including healthy controls and patients with childhood-onset type 1 diabetes, adult-onset type 1 diabetes or type 2 diabetes. All subjects recruited meet the inclusion or exclusion criteria and written informed consent was obtained from each participant at enrollment.

Study Type

OBSERVATIONAL

Enrollment

372

Conditions

Type 1 Diabetes Mellitus Maturity Onset

Eligibility

Sex: ALLMin age: 5 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diabetes diagnosed according to the report of WHO in 1999； 2. Aged between 5 and 70 years old; Exclusion Criteria: 1. Severe chronic cardiovascular or cerebrovascular disease； 2. Severe abnormalities in liver or renal function; 3. Hyperthyroidism; or other autoimmune diseases; 4. Tumors, surgery or pregnancy; 5. Treatments with oral hypoglycemic agents or immunomodulators; 6. Subjects who had taken probiotics, prebiotics within one week or antibiotics within one month.

Locations (1)

Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University

Changsha, Hunan, China

Outcomes

Primary Outcomes

Differences of β diversity of gut microbiota between diabetic groups and healthy control.

β diversity is based on metagenome analysis and statistical significance is estimated by permutational multivariate analysis of variance.

Time frame: at baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.